Merck & Co. Inc. / Aton Pharma Inc.

Cutaneous T-Cell Lymphoma (CTCL)

3K US cases/yr · $123M Zolinza global net sales 2018 (Merck)

Disease Overview

Cutaneous T-cell lymphoma (CTCL) is a rare group of non-Hodgkin lymphomas in which malignant T cells migrate to the skin, producing patches, plaques, and tumors. Mycosis fungoides is the most common subtype. The disease is chronic, progressive, and difficult to treat in late stages, particularly after multiple lines of skin-directed and systemic therapy fail.

Competitive Landscape

At the time of the April 2004 Aton acquisition, advanced CTCL options were limited to bexarotene (Targretin, Ligand/Eisai), denileukin diftitox (Ontak, Ligand/Eisai), photopheresis, and PUVA — none of which delivered durable responses in heavily pre-treated patients. SAHA/vorinostat was positioned as the first-in-class oral histone deacetylase inhibitor for refractory CTCL, with a phase IIb trial showing activity in patients who had exhausted 'a median of three previous therapies' (CancerNetwork, 2006). Merck's $0 (undisclosed) deal for Aton secured exclusive rights to compounds licensed from Memorial Sloan-Kettering and Columbia, where Paul Marks and Ronald Breslow had developed the molecule. The acquisition reframed Merck's oncology pipeline around epigenetic targets and led directly to Zolinza's October 6, 2006 FDA approval — the first HDAC inhibitor in any indication. Romidepsin (Istodax, Gloucester/Celgene) followed in 2009, validating the class. Subsequent CTCL entrants (mogamulizumab/Poteligeo, brentuximab vedotin/Adcetris) reshaped later-line therapy, leaving Zolinza as a declining but still-marketed option. See https://www.cancernetwork.com/view/hdac-inhibitors-much-learn-about-effective-therapy.